The rapid systemic clearance of GUB02647 and GUB03385 makes it conceivable that the anti-obesity efficacy of these PrRP analogues is not ascribed to the parent peptide, but rather determined by potent bioactive metabolite(s) with retained lipidation and high plasma stability. The gene discussed is PRLH; the disease is Obesity.